Mahzi Therapeutics

CLOSING SOON: Developing precision therapies for genetic disorders affecting children

https://wefunder.com/mahzi.therapeutics

Total raised on Wefunder: 352522

Total investors: 147

Quick facts

  • $16M in non-dilutive grant awards from the California Institute for Regenerative Medicine
  • Completing patient enrollment in first-ever gene therapy clinical trial for Pitt-Hopkins syndrome
  • CEO with 20+ years of experience at Merck and rare disease pioneers Genzyme & Ultragenyx
  • Leadership team from Stanford, Cambridge, Yale, UC Berkeley & Weizmann Institute
  • Close collaborations with Pitt Hopkins Foundation & many other patient advocacy groups
  • $60M raised from leading VCs Venrock, HealthCap, Droia Ventures & HBM Partners
  • ️​ Forbes 2026 Feature: “This Biotech Lets Families Invest in its Gene Therapy”
  • Targeting a $16B market with 800+ rare neurogenetic addressable disorders

Team profiles

Featured investor profiles

Invest in Mahzi Therapeutics

CLOSING SOON: Developing precision therapies for genetic disorders affecting children

FIRST GOAL HIT (You can still invest)

$34,537,221

raised from 156+ investors
INVESTMENT TERMS
Preferred Stock
$87.9M pre-money valuation $3.47 per share

What Investors Say

LEAD INVESTOR
Invested $5,000 this round
Mahzi is on a great mission to develop precision genetic therapies for seizure and autism-based disorders in meaningful partnership with patient advocacy groups. Developing targeted genetic therapies for severe, under-served neurodevelopmental disorders like Pitt Hopkins syndrome, WOREE syndrome, and CHD2 deficiency is aligned with critical vision of this company. I’m excited to support Mahzi in moving to the next phase of growth and bringing potential disease-modifying treatments to this very deserving community of patients and families.
What People Say